RxDoctor Payments DataLook up a doctor →

Majd Raouf, MD

Internal Medicine · Washington, DCNPI 1053816066

Payments from drug & device makers

$10,999in general payments, 2019–2025

Across 512 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$3K
  • Viiv Healthcare Company$2K
  • AbbVie$1K
  • Pfizer$710
  • Novo Nordisk$438
  • Lilly USA, LLC$367
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$10,78998%
  • Education$2102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,999 in reported general payments places this provider in the 90th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$63,466
Medicare patients
110
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrezcobixDarunavir/Cobicistat24$58,110
DovatoDolutegravir Sodium/Lamivudine16$55,225
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$42,779
OzempicSemaglutide42$41,527
DescovyEmtricitabine/Tenofov Alafenam13$32,298
TivicayDolutegravir Sodium12$26,657
JardianceEmpagliflozin18$26,382
Testosterone12$4,879
Rosuvastatin Calcium100$1,716
Atorvastatin Calcium102$1,335
Ventolin HfaAlbuterol Sulfate12$674
Losartan Potassium71$671
Amlodipine Besylate77$633
Azelastine Hcl11$528
Olmesartan Medoxomil21$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay$1,986$81,88128 claims
Johnson & JohnsonPrezcobix$106$58,11024 claims
Novo NordiskOzempic$438$41,52742 claims
GileadDescovy$2,596$32,29813 claims
Boehringer IngelheimJardiance$74$26,38218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →